Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS author centre
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS author centre
  • Alerts
  • Subscriptions

Immune reconstitution inflammatory syndrome associated with pulmonary pathogens

Radha Gopal, Rekha R. Rapaka, Jay K. Kolls
European Respiratory Review 2017 26: 160042; DOI: 10.1183/16000617.0042-2016
Radha Gopal
Richard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rekha R. Rapaka
Division of Infectious Diseases and Center for Vaccine Development, University of Maryland Medical Center, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jay K. Kolls
Richard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Jay.Kolls@chp.edu
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Immune reconstitution inflammatory syndrome (IRIS) is an exaggerated immune response to a variety of pathogens in response to antiretroviral therapy-mediated recovery of the immune system in HIV-infected patients. Although IRIS can occur in many organs, pulmonary IRIS, associated with opportunistic infections such as Mycobacterium tuberculosis and Pneumocystis jirovecii, is particularly associated with high morbidity and mortality. The pathology of IRIS is associated with a variety of innate and adaptive immune factors, including CD4+ T-cells, CD8+ T-cells, γδ T-cells, natural killer cells, macrophages, the complement system and surfactant proteins, Toll-like receptors and pro-inflammatory cytokines and chemokines. Although there are numerous reports about the immune factors involved in IRIS, the mechanisms involved in the development of pulmonary IRIS are poorly understood. Here, we propose that studies using gene-deficient murine and nonhuman primate models will help to identify the specific molecular targets associated with the development of IRIS. An improved understanding of the mechanisms involved in the pathology of pulmonary IRIS will help to identify potential biomarkers and therapeutic targets in this syndrome.

Abstract

Mechanisms of pulmonary IRIS in HIV-infected individuals recently initiated on ART are poorly defined http://ow.ly/AAOR301Bh36

Introduction

A variety of opportunistic pathogens including viruses (human herpesvirus-8 and cytomegalovirus), fungi (Cryptococcus, Pneumocystis and Histoplasma) and bacteria (Mycobacterium) [1, 2] are associated with the development of immune reconstitution inflammatory syndrome (IRIS) after initiation of antiretroviral therapy (ART). IRIS presents as one of two forms, characterised by the timing of IRIS diagnosis in relation to the start of ART [3]. Paradoxical IRIS refers to worsening of symptoms secondary to a known opportunistic infection in the setting of the initiation of ART and treatment of the opportunistic infection. The second form is “unmasked” or ART-associated IRIS, in which infection with an opportunistic pathogen is undiagnosed until the initiation of ART [3]. Pulmonary IRIS has been described in Mycobacterium tuberculosis, M. avium complex, Pneumocystis jirovecii, Cryptococcus neoformans and Kaposi's sarcoma and can present with a spectrum of clinical manifestations, including pneumonitis, pulmonary infiltrates, lymphadenopathy, cough and dyspnoea [3, 4]. Low CD4+ cell counts, high antigen load from an opportunistic infection and a short interval between the treatment of an opportunistic infection and the start of ART are risk factors involved in the development of IRIS [5, 6]. Several studies of pulmonary IRIS have suggested that the adaptive immune response, especially an antigen-specific T-cell response to opportunistic infection, is crucial for the development of IRIS [7–9]. However, recent studies have shown that dysregulation of the innate immune system due to opportunistic infection is also a key factor in the subsequent development of IRIS [10, 11]. Although many reports demonstrate a variety of immune factors involved in IRIS, the complexity of the disease process and variation in clinical presentations limit the understanding of the pathogenesis of disease. Thus, more research is necessary to understand the molecular mechanisms associated with the development of IRIS. IRIS has been modelled using T-cell deficient mice or severe combined immunodeficiency (SCID) mice infected with pulmonary pathogens including M. tuberculosis, P. jirovecii and C. neoformans. More studies using these models will help to overcome the limitations in understanding the mechanism involved in IRIS. In this review, we discuss epidemiology, immunopathology, animal models, diagnosis, treatment, prevention strategies and future research of pulmonary infections associated with IRIS.

Clinical presentation and epidemiology of pulmonary IRIS

The incidence of pulmonary IRIS is difficult to measure, given the wide range of possible disease presentations, local incidence of opportunistic infection and variations in local diagnostic capacity. In a retrospective analysis of patients in USA initiating ART after experiencing an opportunistic infection, IRIS was observed within 1 year in 16% of patients with tuberculosis (TB), 10% of patients with M. avium complex infection, 29% of patients with Kaposi's sarcoma and 4% of patients with P. jirovecii infection [12]. An international meta-analysis showed that TB-associated IRIS occurred in 15.7% of patients who were treated for both HIV and TB [13]. Risk of developing IRIS increased with shorter duration between initiation of TB treatment and ART, or with low CD4+ T-cell count at ART initiation [13]. Clinical manifestations of TB-IRIS include weight loss, fever, lymphadenopathy and worsening of pulmonary symptoms, including development of abscesses, respiratory failure, acute respiratory distress syndrome and death. Morbidity and mortality secondary to TB-IRIS may be difficult to assess accurately, given the broad differential for clinical deterioration while on therapy, particularly in resource-limited environments. A post mortem analysis of a cohort of South African patients showed that IRIS secondary to mycobacterial infection was associated with the majority of early deaths occurring within 3 months of initiating ART [14]. World Health Organization guidelines recommend early ART initiation in patients with TB and very low CD4+ T-cell counts, as there are increased risks associated with delaying ART, such as death from another opportunistic infection, compared to complications from IRIS. Given these newer guidelines, with increasing numbers of patients starting ART with lower CD4+ T-cell counts, the global incidence of IRIS may rise [15].

IRIS associated with P. jirovecii infection presents as a worsening of existing Pneumocystis pneumonia (PCP) or unmasking of a previously asymptomatic infection. While many patients exhibit an inflammatory response upon initiation of antibiotics directed against Pneumocystis tempered by treatment with steroids, patients may also have worsening of pulmonary disease after initiation of ART, with symptoms of fever, dyspnoea, worsening hypoxia and increased inflammatory cells on bronchoscopy [16]. An analysis of published case reports of PCP shows that the IRIS syndrome tends to present early, at a median 15 days after initiation of ART [17].

IRIS associated with M. avium complex infection usually presents as either focal or diffuse lymphadenitis, occurring typically within 3 months of initiation of ART, and often with suppuration. M. avium complex related IRIS rarely presents as focal pulmonary disease [18].

Cryptococcosis manifests frequently as a multiorgan disease process, affecting the brain, lungs and skin; and while cryptococcal IRIS usually involves meningeal disease, pulmonary cryptococcal IRIS may present as a pneumonitis, or as cavitary or nodular lesions [3]. In some instances of Cryptococcus-associated IRIS, relapse of infection is increased after treatment for suspected IRIS given use of steroids for treatment.

Kaposi's sarcoma-associated IRIS (KS-IRIS) manifests as progression of lesions in the context of initiation of ART, and is noted to have high morbidity and mortality, especially in the setting of visceral disease, which frequently affects the lungs and gastrointestinal tract [19]. One US cohort exhibited an incidence of 16% within 1 year of starting ART [12]. Increased susceptibility to KS-IRIS correlates with a rapid rate of CD4+ T-cell increase during ART, as well as peripheral oedema consistent with advanced-stage Kaposi's sarcoma [20].

Studies of the incidence of IRIS in children are limited. In a multicentre study in Uganda, IRIS was observed in 38% of paediatric patients in the first 6 months of ART therapy, predominantly in patients co-infected with TB or bacterial pneumonia [21].

Immunopathology of pulmonary IRIS

Several components of the immune system, including T-cells, macrophages, natural killer (NK) cells, pro-inflammatory cytokines and chemokines are involved in the pathology of IRIS (figure 1). In particular, increases in antigen-specific CD4+ T-cells were observed in IRIS patients regardless of the opportunistic infection involved [7, 8]. Furthermore, increased numbers of CD8+ T-cells were observed in IRIS patients when compared to non-IRIS controls [22]. Recent studies have shown the involvement of the memory T-cell population in the pathogenesis of IRIS. Thus, increased frequencies of CD4+ cells expressing programmed cell death protein-1, Ki67, high levels of human leukocyte antigen D-related and effector memory population markers were observed in patients developing IRIS when compared to non-IRIS controls [8]. Pro-inflammatory cytokines and chemokines are other important factors in the exaggerated inflammatory response. Accordingly, elevated serum interleukin (IL)-6, C-X-C motif chemokine ligand (CXCL)-8, tumour necrosis factor (TNF)-α and interferon (IFN)-γ were observed in patients during the development of IRIS [23, 24]. Moreover, recent studies have shown that innate immune factors such as macrophages, monocytes, γδ T-cells, NK cells and the complement system also play a major role in IRIS associated with opportunistic infection [11, 24–27].

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Immune reconstitution inflammatory syndrome (IRIS) associated with Mycobacterium tuberculosis (TB) infection. a) In healthy individuals in response to M. tuberculosis infection, macrophages and dendritic cells induce polarising cytokines including interleukin (IL)-6, IL-12 and IL-23. These cytokines polarise T-cells which in turn activate macrophages to kill M. tuberculosis. b) In HIV-infected patients there is no M. tuberculosis control because of lack of effective T-cell responses. IRIS develops in HIV-infected patients with pre-antiretroviral therapy (ART) risk factors, such as low CD4+ cells, high HIV viral load, high M. tuberculosis antigen load and a short interval between M. tuberculosis treatment and ART. A variety of innate and adaptive immune cells, pro-inflammatory cytokines, chemokines and matrix metalloproteinases (MMPs) are involved in the exaggerated inflammatory response seen in IRIS. IFN: interferon; Th: T-helper cell; NK: natural killer; TLR: Toll-like receptor; CXCL: C-X-C motif chemokine ligand; TNF: tumour necrosis factor; CRP: C-reactive protein.

Immunopathology of IRIS associated with TB

Immune responses in patients with TB-IRIS demonstrate an important role for T-cell-mediated inflammatory responses [7, 8]. Several studies have shown the role of T-helper (Th) type 1 cells and relevant cytokines IFN-γ and TNF-α in the pathology associated with TB-IRIS. Accordingly, higher frequencies of IFN-γ+ T-cells specific to M. tuberculosis antigens such as early secretory antigenic target-6, α-crystallin 1, α-crystallin 2 and purified protein derivative were observed in TB-IRIS patients than non-IRIS patients [25]. However, in some cohorts, antigen-specific IFN-γ responses were similar in both TB-IRIS patients and non-IRIS controls [28]. Recent studies have shown an increase in effector memory CD4+ T-cell frequencies in TB-IRIS patients when compared to non-IRIS controls [29]. Moreover, elevated levels of the soluble IL-2 receptor sCD25 suggest a role for CD4+ T-cells in the pathogenesis of TB-IRIS [30]. Th17 cells produce the cytokines IL-17, IL-22 and IL-21 following stimulation with polarising cytokines IL-23, IL-1β and IL-6. Many studies have shown an elevated level of IL-6, a critical driver of Th17 cells, in TB-IRIS [11, 31, 32]. A retrospective analysis of a randomised trial reported the elevation of Th17 cytokines in IRIS patients, suggesting a role for Th17 cells [23]. T regulatory (Treg) cells are known to be involved in maintaining immune system balance by suppressing the pathological effect mediated by Th1 responses. While one study demonstrated the presence of CD4+ FoxP3+ cells in TB-IRIS patients, their role in the development of TB-IRIS is not clear [25].

Innate immune cells such as macrophages and monocytes are implicated in the pathogenesis of IRIS [10, 33]. Accordingly, an elevated CD14+CD16− monocyte population and an increase in the pro-inflammatory cytokines IL-6, TNF-α and C- reactive protein (CRP) were observed in TB-IRIS patients prior to the initiation of ART [32]. Furthermore, microarray analysis of monocytes from TB-IRIS patients showed dysregulation in pathways related to pattern recognition receptors, peroxisome proliferator-activated receptors, IL-6 and IL-10 during pre-ART [33]. Studies have shown the involvement of the complement system [10], as well as signalling via Toll-like receptors and triggering receptors expressed on myeloid cells-1 [34] in the development of TB-IRIS. Moreover, one study has demonstrated that CD68+ macrophages were the predominant inflammatory cell population identified by immunohistochemistry in lung tissue from TB-IRIS patients [35]. Inflammatory cytokines and chemokines induced by macrophages and dendritic cells have also been shown to be involved in TB-IRIS. Accordingly, increases in IL-6, IL-1β, CXCL8, IL-10, IL-18 and CC chemokine ligand (CCL)2 were observed during pre-ART in HIV patients who subsequently developed TB-IRIS [29, 31, 36]. Additionally, IL-6 [11] and IL-18 [36] have been identified as potential biomarkers of TB-IRIS. In addition to macrophages and monocytes, γδ T-cells and NK cells are implicated in TB-IRIS. Studies have shown elevated frequencies of Kir-γδ T-cells [37] and CD69+ NK cells [38] in TB-IRIS patients during pre-ART, suggesting that these cells may play a role in IRIS-associated pathology. Furthermore, one study demonstrated increased levels of CD107a, marker of NK cell degranulation in TB-IRIS patients during pre-ART [39]. These studies suggest a requirement for both innate and adaptive immunity in the pathogenesis of IRIS (figure 1).

Matrix metalloproteinases (MMPs) are a group of proteases involved in the degradation of various components of the extracellular matrix and which play a pathological role in inflammation, cancer and arthritis. It has been shown that MMP-mediated collagen degradation is a possible mechanism for TB-associated lung damage [40, 41]. Accordingly, one study has shown increased expression of MMP-1, -3, -7 and -10 in peripheral blood mononuclear cells from TB-IRIS patients [42]. Another study has shown that increases in MMP-8 levels following ART were associated with impaired lung function in TB-IRIS [43]. These studies suggest that in addition to the innate and adaptive immune system response, MMPs also play a major role in the pathology caused by TB-IRIS.

IRIS-associated Mycobacterium avium complex infection has been modelled using T-cell antigen receptor (TCR)-α−/− mice with M. avium infection [9]. In this model, TCR-α−/− mice were infected with M. avium for 2–3 months followed by reconstitution of CD4+ T-cells from both spleen and lymph nodes [44]. It was demonstrated in this model that an antigen-specific CD4+ T-cell response was crucial for the development of IRIS [9]. Additionally, increased levels of IL-6 and CRP were observed during the immune reconstitution process [11]. Moreover, this model demonstrated that the induction of CRP is IL-6 dependent. However, the induction of IL-6 is not dependent on IFN-γ production from T-cells transferred during experimental IRIS-associated M. avium infection. Furthermore, it has been shown that combined neutralisation of IFN-γ and IL-6 increased survival and pathology in this model [11].

Immunopathology of IRIS associated with fungal infections

Despite decreases in the incidence of PCP following the introduction of anti-Pneumocystis prophylaxis and ART, some people develop paradoxical IRIS following antiretroviral therapy [12, 13]. One case series demonstrated that decreased CD4+ T-cell count and high HIV viral burden during pre-ART are associated with the development of PCP-IRIS following ART [45]. Another study has shown increased levels of CD4 and CD8 cells following ART in an HIV patient due to PCP-IRIS [16].

IRIS associated P. murina was first modelled in Rag1−/− and SCID mice [46, 47]. These immunodeficient mice were infected with P. murina for 2 weeks followed by reconstitution with whole splenocytes or CD4+ T-cells [46, 47]. Using this model, it has been demonstrated that CD4+ T-cells contribute the pathological immune response in PCP-IRIS. However, CD8+ T-cells are the major inflammatory mediators in the absence of CD4+ cells in PCP-IRIS [48]. The degree of lung injury in this model is driven by the fungal burden as well as the number of transferred cells. T-cells are known to be involved in suppressing the autoimmune response as well as hyperinflammation mediated through CD4+ T-cells. Accordingly, it has been shown that depletion of Treg cells exacerbates IRIS in this model [47]. Lung injury associated with PCP-IRIS manifests with hypoxaemia, elevated lactate dehydrogenase and total protein in bronchoalveolar lavage fluid, weight loss and mortality [46, 47, 49]. A recent study using Rag1−/−IFN-γR−/− or Rag1−/−IL-4R−/− mouse models of IRIS demonstrated that the activation of M1 or M2 macrophages is not required for Pneumocystis clearance [50]. Furthermore, this study has shown that IFN-γ is a critical mediator in the exacerbated inflammatory response by decreasing the CD8+Foxp3+ regulatory T-cell subset in PCP-IRIS [50]. Dectin-1 is involved in PCP-IRIS dependent lung injury, as antagonising dectin-1 signalling blocked the development of fungal IRIS [51]. B-cells are critical for effective CD4+ T-cell response to control Pneumocystis infection [49, 52]. However, there are no current data supporting a role for B-cells in regulating the pathology associated with PCP-IRIS [49].

Pulmonary surfactants are lipoproteins that maintain surface tension in the lungs and protect the lungs from injury. Studies have shown that pathology in PCP is associated with decreased levels of surfactant protein (SP)-B and increased levels of SP-D [53, 54]. Recent studies have demonstrated that the immune reconstitution in IRIS is associated with the dysregulation of surfactant compounds in the lungs, increased pro-inflammatory cell recruitment [54] and exaggerated inflammation [55].

As in TB-IRIS, increased levels of IFN-γ, TNF-α, IL-6, CXCL8, granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor before the start of ART were observed in cryptococcal IRIS patients [56]. Accordingly, these cytokines and chemokines were proposed to be potential biomarkers of cryptococcal IRIS [56]. The upregulation of chemokines CXCL10, CCL2 and CCL3 suggest a role for both T-cells and monocytes, reinforcing the interaction of innate and adaptive immunity in the pathogenesis of IRIS [57].

IRIS associated with Cryptococcus was modelled in the mouse successfully, in which RAG−/− mice were infected with C. neoformans and transferred with CD4+ T-cells after 4 weeks. The data show the development of multiorgan immune reconstitution disease and systemic increases in the pro-inflammatory cytokines IFN-γ, IL-6 and TNF-α [58].

Diagnosis of IRIS

There is no single diagnostic test currently available for IRIS. Therefore, information regarding the opportunistic infection involved, diagnosis, treatment and response to treatment of opportunistic infection before the start of ART is crucial to the diagnosis of “paradoxical” IRIS. Diagnosis is further complicated in patients with “unmasking” IRIS, as it is difficult to prove both the previous existence of a hidden opportunistic infection and that the observed increase in inflammation is due to immune recovery. Thus, French et al. [59] recommended two major and three minor criteria for the diagnosis of IRIS. They defined these two major criteria as identification of atypical presentation of opportunistic infection and decrease in HIV RNA expression by >1 log10 after ART [59]. The three minor criteria are defined as an increase in CD4+ cell count, increase in immunological response to opportunistic infection and spontaneous recovery of clinical symptoms [59]. In addition, some studies focus on the relationship between the decrease in viral load and increase in CD4+ cell count after ART in the diagnosis of IRIS [6, 60]. However, the confirmatory diagnosis is often complicated due to factors such as drug resistance, drug interactions, treatment failure of the opportunistic infection and other possible opportunistic infections [61]. In TB-IRIS, the increase in drug resistance and emergence of extensively drug-resistant strains of TB in endemic areas add additional levels of complexity to diagnosis [62]. Although there are several studies that identify biomarkers for early diagnosis of IRIS, all of these factors must be considered for proper diagnosis and treatment.

Treatment of IRIS

Corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may be helpful in the management of IRIS. In a study of patients newly initiated on ART with paradoxical TB-IRIS, patients received prednisone over 1 month in conjunction with antimicrobial therapy [63]. Addition of prednisone reduced TB-IRIS symptoms, number of days hospitalised, need for procedures and inflammatory markers [63]. In cases of pulmonary cryptococcal IRIS, corticosteroid treatment may be considered if acute respiratory distress syndrome is present in the context of IRIS [64]. The antifungal regimen should be intensified in patients experiencing complications of cryptococcal IRIS. In addition to corticosteroids and NSAIDs, medications such as thalidomide [65], hydroxychloroquine [66] and TNF-α inhibitors [67] are under investigation as possible anti-inflammatory agents in the treatment of IRIS. In all cases of IRIS, regardless of the opportunistic infections involved, ART should be continued unless there is risk of permanent sequelae from continuation or the patient's life is in danger [1].

Prevention strategies

The development of IRIS is based on the presence of residual antigens from opportunistic infection during recovery. Therefore, the diagnosis and treatment of opportunistic infection before the start of ART is important for the prevention of IRIS. Screening all patients for possible opportunistic infections before starting ART is recommended in TB-endemic areas [68]. Studies show that using this approach in South African cohorts substantially reduced the unmasking of TB before the start of ART [68, 69]. The timing of the start of the ART is crucial in preventing paradoxical IRIS. According to a trial that evaluated starting antiretroviral therapy at three points in TB (SAPiT), ART initiation in TB–HIV patients should be decided based on their CD4 cell counts [70]. If the CD4 counts are <50 cells·mm−3, ART can be started immediately after the initiation of TB treatment. If the CD4+ cell counts are ≥50 cells·mm−3, ART can be delayed [70]. In cases of cryptococcal-HIV co-infection, the timing of start of ART is crucial in controlling IRIS. Longley et al. [2] recommended starting ART 3 weeks after amphotericin B and 4 weeks after fluconazole treatment. In cases of PCP-HIV co-infection, it is recommended that ART be started within 2 weeks of treatment of opportunistic infection, based on a study that evaluated early ART and deferred ART [71].

Conclusions and future directions

Multiple pathogens cause IRIS, which can manifest systemically or localise to the lung. The pathogenesis of IRIS is dependent on multiple factors including CD4+ T-cells, pro-inflammatory cytokines, macrophages and other innate immune cells. More research is needed regarding the molecular mechanisms of IRIS to decipher crucial pathways in this aberrant immunological response which has severe consequences for the host. Although there are numerous reports defining biomarkers of IRIS, variations in clinical presentations and complexity of the disease process limit understanding of the mechanisms involved in immunopathogenesis. Furthermore, an understanding of the interplay between the innate and adaptive immune systems is crucial in identifying the mechanisms involved in the pathogenesis of IRIS. IRIS has been modelled using T-cell-deficient mice infected with pathogens implicated in pulmonary IRIS. Use of gene-deficient mouse models and nonhuman primate models will help to illuminate the gaps left by clinical studies, and will help to identify potential drug targets in preventing and treating pulmonary IRIS.

Disclosures

Supplementary Material

J.K. Kolls ERR-0042-2016_Kolls

Footnotes

  • Support statement. Funding was received from the US Department of Health and Human Science, the National Institutes of Health and the National Heart, Lung and Blood Institute with grant number R37 HL079142. Funding information for this article has been deposited with the Open Funder Registry.

  • Conflict of interest: Disclosures can be found alongside this article at err.ersjournals.com

  • Provenance: Submitted article, peer reviewed.

  • Received April 25, 2016.
  • Accepted June 9, 2016.
  • Copyright ©ERS 2017.

ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Meintjes G,
    2. Scriven J,
    3. Marais S
    . Management of the immune reconstitution inflammatory syndrome. Curr HIV/AIDS Rep 2012; 9: 238–250.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Longley N,
    2. Harrison TS,
    3. Jarvis JN
    . Cryptococcal immune reconstitution inflammatory syndrome. Curr Opin Infect Dis 2013; 26: 26–34.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Haddow LJ,
    2. Colebunders R,
    3. Meintjes G, et al.
    Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis 2010; 10: 791–802.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Leone S,
    2. Nicastri E,
    3. Giglio S, et al.
    Immune reconstitution inflammatory syndrome associated with Mycobacterium tuberculosis infection: a systematic review. Int J Infect Dis 2010; 14: e283–e291.
    OpenUrlPubMed
  5. ↵
    1. Ratnam I,
    2. Chiu C,
    3. Kandala NB, et al.
    Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006; 42: 418–427.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Shelburne SA,
    2. Visnegarwala F,
    3. Darcourt J, et al.
    Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19: 399–406.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Bourgarit A,
    2. Carcelain G,
    3. Martinez V, et al.
    Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 2006; 20: F1–F7.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Antonelli LR,
    2. Mahnke Y,
    3. Hodge JN, et al.
    Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood 2010; 116: 3818–3827.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Barber DL,
    2. Mayer-Barber KD,
    3. Antonelli LR, et al.
    Th1-driven immune reconstitution disease in Mycobacterium avium-infected mice. Blood 2010; 116: 3485–3493.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Tran HT,
    2. Van den Bergh R,
    3. Loembé MM, et al.
    Modulation of the complement system in monocytes contributes to tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2013; 27: 1725–1734.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Barber DL,
    2. Andrade,
    3. McBerry C, et al.
    Role of IL-6 in Mycobacterium avium-associated immune reconstitution inflammatory syndrome. J Immunol 2014; 192: 676–682.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Achenbach CJ,
    2. Harrington RD,
    3. Dhanireddy S, et al.
    Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. Clin Infect Dis 2012; 54: 424–433.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Müller M,
    2. Wandel S,
    3. Colebunders R, et al.
    Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 251–261.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Wong EB,
    2. Omar T,
    3. Setlhako GJ, et al.
    Causes of death on antiretroviral therapy: a post-mortem study from South Africa. PLoS One 2012; 7: e47542.
    OpenUrlCrossRefPubMed
  15. ↵
    World Health Organization. Guidelines for Treatment of Tuberculosis. 4th Edn. Geneva, Switzerland, WHO Press, 2010; p. 70.
  16. ↵
    1. Barry SM,
    2. Lipman MC,
    3. Deery AR, et al.
    Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV-infected subjects. HIV Med 2002; 3: 207–211.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Mok HP,
    2. Hart E,
    3. Venkatesan P
    . Early development of immune reconstitution inflammatory syndrome related to Pneumocystis pneumonia after antiretroviral therapy. Int J STD AIDS 2014; 25: 373–377.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Lawn SD,
    2. Bekker LG,
    3. Miller RF
    . Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5: 361–373.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Leidner RS,
    2. Aboulafia DM
    . Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS 2005; 19: 635–644.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Feller L,
    2. Lemmer J
    . Insights into pathogenic events of HIV-associated Kaposi sarcoma and immune reconstitution syndrome related Kaposi sarcoma. Infect Agent Cancer 2008; 3: 1.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Orikiiriza J,
    2. Bakeera-Kitaka S,
    3. Musiime V, et al.
    The clinical pattern, prevalence, and factors associated with immune reconstitution inflammatory syndrome in Ugandan children. AIDS 2010; 24: 2009–2017.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Espinosa E,
    2. Romero-Rodríguez DP,
    3. Cantoral-Díaz MT, et al.
    Transient expansion of activated CD8+ T cells characterizes tuberculosis-associated immune reconstitution inflammatory syndrome in patients with HIV: a case control study. J Inflamm 2013; 10: 21.
    OpenUrl
  23. ↵
    1. Grant PM,
    2. Komarow L,
    3. Lederman MM, et al.
    Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164. J Infect Dis 2012; 206: 1715–1723.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Boulware DR,
    2. Meya DB,
    3. Bergemann TL, et al.
    Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med 2010; 7: e1000384.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Meintjes G,
    2. Wilkinson KA,
    3. Rangaka MX, et al.
    Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2008; 178: 1083–1089.
    OpenUrlCrossRefPubMed
    1. Goovaerts O,
    2. Jennes W,
    3. Massinga-Loembé M, et al.
    LPS-binding protein and IL-6 mark paradoxical tuberculosis immune reconstitution inflammatory syndrome in HIV patients. PLoS One 2013; 8: e81856.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Narendran G,
    2. Andrade BB,
    3. Porter BO, et al.
    Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in HIV patients with culture confirmed pulmonary tuberculosis in India and the potential role of IL-6 in prediction. PLoS One 2013; 8: e63541.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Goovaerts O,
    2. Jennes W,
    3. Massinga-Loembé M, et al.
    Antigen-specific interferon-gamma responses and innate cytokine balance in TB-IRIS. PLoS One 2014; 9: e113101.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Haridas V,
    2. Pean P,
    3. Jasenosky LD, et al.
    TB-IRIS, T-cell activation, and remodeling of the T-cell compartment in highly immunosuppressed HIV-infected patients with TB. AIDS 2015; 29: 263–273.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Chakrabarti LA,
    2. Boucherie C,
    3. Bugault F, et al.
    Biomarkers of CD4+ T-cell activation as risk factors for tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2014; 28: 1593–1602.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Ravimohan S,
    2. Tamuhla N,
    3. Steenhoff AP, et al.
    Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospective observational cohort study. Lancet Infect Dis 2015; 15: 429–438.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Andrade BB,
    2. Singh A,
    3. Narendran G, et al.
    Mycobacterial antigen driven activation of CD14++CD16− monocytes is a predictor of tuberculosis-associated immune reconstitution inflammatory syndrome. PLoS Pathog 2014; 10: e1004433.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Tran HT,
    2. Van den Bergh R,
    3. Vu TN, et al.
    The role of monocytes in the development of tuberculosis-associated immune reconstitution inflammatory syndrome. Immunobiology 2014; 219: 37–44.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Lai RP,
    2. Meintjes G,
    3. Wilkinson KA, et al.
    HIV-tuberculosis-associated immune reconstitution inflammatory syndrome is characterized by Toll-like receptor and inflammasome signalling. Nat Commun 2015; 6: 8451.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Lawn SD,
    2. Wainwright H,
    3. Orrell C
    . Fatal unmasking tuberculosis immune reconstitution disease with bronchiolitis obliterans organizing pneumonia: the role of macrophages. AIDS 2009; 23: 143–145.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Tan HY,
    2. Yong YK,
    3. Andrade BB, et al.
    Plasma interleukin-18 levels are a biomarker of innate immune responses that predict and characterize tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2015; 29: 421–431.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Bourgarit A,
    2. Carcelain G,
    3. Samri A, et al.
    Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculin-specific CD4 Th1 cells and KIR-negative γδ T cells. J Immunol 2009; 183: 3915–3923.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Conradie F,
    2. Foulkes AS,
    3. Ive P, et al.
    Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection. J Acquir Immune Defic Syndr 2011; 58: 309–318.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Pean P,
    2. Nerrienet E,
    3. Madec Y, et al.
    Natural killer cell degranulation capacity predicts early onset of the immune reconstitution inflammatory syndrome [IRIS] in HIV-infected patients with tuberculosis. Blood 2012; 119: 3315–3320.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Greenlee KJ,
    2. Werb Z,
    3. Kheradmand F
    . Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted. Physiol Rev 2007; 87: 69–98.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. Elkington PT,
    2. Ugarte-Gil CA,
    3. Friedland JS
    . Matrix metalloproteinases in tuberculosis. Eur Respir J 2011; 38: 456–464.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Tadokera R,
    2. Meintjes GA,
    3. Wilkinson KA, et al.
    Matrix metalloproteinases and tissue damage in HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur J Immunol 2014; 44: 127–136.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Ravimohan S,
    2. Tamuhla N,
    3. Kung SJ, et al.
    Matrix metalloproteinases in tuberculosis-immune reconstitution inflammatory syndrome and impaired lung function among advanced HIV/TB co-infected patients initiating antiretroviral therapy. EBioMedicine 2015; 3: 100–107.
    OpenUrl
  43. ↵
    1. Barber DL,
    2. Andrade BB,
    3. Sereti I, et al.
    Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none. Nat Rev Microbiol 2012; 10: 150–156.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Jagannathan P,
    2. Davis E,
    3. Jacobson M, et al.
    Life-threatening immune reconstitution inflammatory syndrome after Pneumocystis pneumonia: a cautionary case series. AIDS 2009; 23: 1794–1796.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Wright TW,
    2. Gigliotti F,
    3. Finkelstein JN, et al.
    Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest 1999; 104: 1307–1317.
    OpenUrlCrossRefPubMed
  46. ↵
    1. McKinley L,
    2. Logar AJ,
    3. McAllister F, et al.
    Regulatory T cells dampen pulmonary inflammation and lung injury in an animal model of Pneumocystis pneumonia. J Immunol 2006; 177: 6215–6226.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Bhagwat SP,
    2. Gigliotti F,
    3. Xu H, et al.
    Contribution of T cell subsets to the pathophysiology of Pneumocystis-related immunorestitution disease. Am J Physiol Lung Cell Mol Physiol 2006; 291: L1256–L1266.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Elsegeiny W,
    2. Eddens T,
    3. Chen K, et al.
    Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia. Infect Immun 2015; 83: 2043–2052.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Zhang ZQ,
    2. Wang J,
    3. Hoy Z, et al.
    Neither classical nor alternative macrophage activation is required for Pneumocystis clearance during immune reconstitution inflammatory syndrome. Infect Immun 2015; 83: 4594–4603.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Ricks DM,
    2. Chen K,
    3. Zheng M, et al.
    Dectin immunoadhesins and Pneumocystis pneumonia. Infect Immun 2013; 81: 3451–3462.
    OpenUrlAbstract/FREE Full Text
  51. ↵
    1. Opata MM,
    2. Hollifield ML,
    3. Lund FE, et al.
    B lymphocytes are required during the early priming of CD4+ T cells for clearance of Pneumocystis infection in mice. J Immunol 2015; 195: 611–620.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. Wright TW,
    2. Notter RH,
    3. Wang Z, et al.
    Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia. Infect Immun 2001; 69: 758–764.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Atochina-Vasserman EN,
    2. Gow AJ,
    3. Abramova H, et al.
    Immune reconstitution during Pneumocystis lung infection: disruption of surfactant component expression and function by S-nitrosylation. J Immunol 2009; 182: 2277–2287.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    1. Eddens T,
    2. Kolls JK
    . Pathological and protective immunity to Pneumocystis infection. Semin Immunopathol 2015; 37: 153–162.
    OpenUrlCrossRef
  55. ↵
    1. Boulware DR,
    2. Bonham SC,
    3. Meya DB, et al.
    Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis 2010; 202: 962–970.
    OpenUrlAbstract/FREE Full Text
  56. ↵
    1. Chang CC,
    2. Lim A,
    3. Omarjee S, et al.
    Cryptococcosis-IRIS is associated with lower cryptococcus-specific IFN-γ responses before antiretroviral therapy but not higher T-cell responses during therapy. J Infect Dis 2013; 208: 898–906.
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. Eschke M,
    2. Piehler D,
    3. Schulze B, et al.
    A novel experimental model of Cryptococcus neoformans-related immune reconstitution inflammatory syndrome (IRIS) provides insights into pathogenesis. Eur J Immunol 2015; 45: 3339–3350.
    OpenUrl
  58. ↵
    1. French MA,
    2. Price P,
    3. Stone SF
    . Immune restoration disease after antiretroviral therapy. AIDS 2004; 18: 1615–1627.
    OpenUrlCrossRefPubMed
  59. ↵
    1. Shelburne SA,
    2. Montes M,
    3. Hamill RJ
    . Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006; 57: 167–170.
    OpenUrlAbstract/FREE Full Text
  60. ↵
    1. Marais S,
    2. Wilkinson RJ,
    3. Pepper DJ, et al.
    Management of patients with the immune reconstitution inflammatory syndrome. Curr HIV/AIDS Rep 2009; 6: 162–171.
    OpenUrlCrossRefPubMed
  61. ↵
    1. Meintjes G,
    2. Rangaka MX,
    3. Maartens G, et al.
    Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis 2009; 48: 667–676.
    OpenUrlAbstract/FREE Full Text
  62. ↵
    1. Meintjes G,
    2. Wilkinson RJ,
    3. Morroni C, et al.
    Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010; 24: 2381–2390.
    OpenUrlCrossRefPubMed
  63. ↵
    1. Perfect JR,
    2. Dismukes WE,
    3. Dromer F, et al.
    Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50: 291–322.
    OpenUrlAbstract/FREE Full Text
  64. ↵
    1. Lortholary O,
    2. Fontanet A,
    3. Mémain N, et al.
    Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005; 19: 1043–1049.
    OpenUrlCrossRefPubMed
  65. ↵
    1. Boelaert JR,
    2. Goddeeris KH,
    3. Vanopdenbosch LJ, et al.
    Relapsing meningitis caused by persistent cryptococcal antigens and immune reconstitution after the initiation of highly active antiretroviral therapy. AIDS 2004; 18: 1223–1224.
    OpenUrlCrossRefPubMed
  66. ↵
    1. Blackmore TK,
    2. Manning L,
    3. Taylor WJ, et al.
    Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis 2008; 47: e83–e85.
    OpenUrlAbstract/FREE Full Text
  67. ↵
    1. Bassett IV,
    2. Wang B,
    3. Chetty S, et al.
    Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 2010; 51: 823–829.
    OpenUrlAbstract/FREE Full Text
  68. ↵
    1. Lawn SD,
    2. Kranzer K,
    3. Edwards DJ, et al.
    Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS 2010; 24: 1323–1328.
    OpenUrlPubMed
  69. ↵
    1. Naidoo K,
    2. Yende-Zuma N,
    3. Padayatchi N, et al.
    The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med 2012; 157: 313–324.
    OpenUrlCrossRefPubMed
  70. ↵
    1. Zolopa A,
    2. Andersen J,
    3. Powderly W, et al.
    Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4: e5575.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 26 Issue 143 Table of Contents
European Respiratory Review: 26 (143)
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Immune reconstitution inflammatory syndrome associated with pulmonary pathogens
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Immune reconstitution inflammatory syndrome associated with pulmonary pathogens
Radha Gopal, Rekha R. Rapaka, Jay K. Kolls
European Respiratory Review Mar 2017, 26 (143) 160042; DOI: 10.1183/16000617.0042-2016

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Immune reconstitution inflammatory syndrome associated with pulmonary pathogens
Radha Gopal, Rekha R. Rapaka, Jay K. Kolls
European Respiratory Review Mar 2017, 26 (143) 160042; DOI: 10.1183/16000617.0042-2016
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Clinical presentation and epidemiology of pulmonary IRIS
    • Immunopathology of pulmonary IRIS
    • Immunopathology of IRIS associated with TB
    • Immunopathology of IRIS associated with fungal infections
    • Diagnosis of IRIS
    • Treatment of IRIS
    • Prevention strategies
    • Conclusions and future directions
    • Disclosures
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Mechanisms of lung disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • COPD and air travel
  • COPD stands for complex obstructive pulmonary disease
  • Indoor mould exposure, asthma and rhinitis
Show more Reviews

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERR

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising
  • Sponsorship

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Collections
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 0905-9180
Online ISSN: 1600-0617

Copyright © 2019 by the European Respiratory Society